Drugs / GB-7624
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06920693 | Mar 2025 → Aug 2026 overdue | atopic eczema | Generate Biomedicines | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-7624 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06920693 ↗ |
| Route | Subcutaneous | “GB-7624 Administered Subcutaneously” NCT06920693 ↗ |